Main Content

News and Announcements


FMI has provided the Genomic Data Commons (GDC) with genomic profiling data from approximately 18,000 adult patients with a diverse array of cancers that underwent genomic profiling using FoundationOne®, FMI's commercially available, comprehensive genomic profiling assay. FMI routinely analyzes cancer specimens using the advanced sequencing technology of FoundationOne.

The Navigating the GDC - A Case Study webinar is the first webinar in a series of NCI GDC Webinar. This webinar will help introduce users to the different GDC tools and data types that are available to support cancer genomic analysis. As an example, we will identify common p53 mutations in colon cancer in the GDC cBioPortal, verify mutation calls using BAM slicing in the GDC Data Portal, and investigate the impact of mutations on RNA-Seq expression. In the process we will also highlight the GDC Data Transfer Tool, harmonized clinical data, and the GDC API.

The NCI announced a collaboration with the Multiple Myeloma Research Foundation (MMRF) to integrate MMRF's wealth of genomic and clinical data on the disease into the GDC. The MMRF is the first non-profit to donate information to the GDC and serves as a research and advocacy organization conducting clinical studies that incorporate whole-genome, whole-exome, and RNA sequencing into their study analyses.

Today the National Cancer Institute signed an agreement with Foundation Medicine, Inc. (FMI) that will grow the number of cancer cases represented at the GDC to well over 30,000 individuals. The agreement will make FMI-generated comprehensive genomic variant information for a set of cancer-associated genes from over 18,000 adult cancer cases available through the GDC to dbGaP-authorized users.

The NCI’s Genomic Data Commons (GDC) was officially launched on June 6th at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting by Vice President Joe Biden as part of the National Cancer Moonshot Initiative. The GDC is an interactive data sharing platform that enables the access, standardization, analysis, and submission of cancer genomic data in support of precision medicine.

The NCI’s Genomic Data Commons (GDC) project completes Phase 3 activities. In Phase 3, the GDC generates high level data including DNA-Seq derived germline variants and somatic mutations, RNA-Seq and miRNA-Seq derived gene and miRNA quantifications, and SNP Array based copy number segmentations.

The NCI's Genomic Data Commons (GDC) project completes Phase 2 activities. In Phase 2, the GDC provides support for data submission and harmonization to GRCh38, the latest reference genome build (GRCh38).

The Genomic Data Commons project will help researchers around the country assess genetic information from more than 10,000 cancer patients, which could be used to develop more effective treatments, said Robert Grossman, a professor of medicine at the University of Chicago who is directing the project.

The NCI's Genomic Data Commons (GDC) project completes Phase 1 activities. In Phase 1, GDC provides support for TCGA datasets made accessible via the GDC Data Portal and the GDC Data Transfer Tool.

The National Cancer Institute is establishing the NCI Genomic Data Commons (GDC) to store, analyze and distribute cancer genomics data generated by NCI and other research organizations. The GDC will provide an interactive system for researchers to access data, with the goal of advancing the molecular diagnosis of cancer and suggest potential therapeutic targets based on genomic information. The GDC is the first step toward the development of a knowledge system for cancer, as originally recommended in a 2011 Institute of Medicine (IOM) report, "Toward Precision Medicine."

The University of Chicago and the NCI are collaborating to establish the Genomic Data Commons (GDC). The GDC is a first-of-its-kind facility that will be the most comprehensive system to store data from NCI-funded research programs in a single repository, and harmonize them so they’re compatible. The GDC addresses a major issue in cancer research. A wealth of valuable tumor genome data has been collected by NCI-funded projects, but most researchers can’t make use of the material due to sheer size, disparate formats and dispersed storage locations.